Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
BIOD's Cash to Debt is ranked higher than
92% of the 1256 Companies
in the Global Biotechnology industry.

( Industry Median: 47.96 vs. BIOD: No Debt )
BIOD' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt

Interest Coverage No Debt
BIOD's Interest Coverage is ranked higher than
86% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. BIOD: No Debt )
BIOD' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 2
Z-Score: -4.98
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -53.67
BIOD's ROE (%) is ranked higher than
67% of the 1151 Companies
in the Global Biotechnology industry.

( Industry Median: -34.30 vs. BIOD: -53.67 )
BIOD' s 10-Year ROE (%) Range
Min: -1034.56   Max: -34.65
Current: -53.67

-1034.56
-34.65
ROA (%) -44.26
BIOD's ROA (%) is ranked higher than
66% of the 1260 Companies
in the Global Biotechnology industry.

( Industry Median: -26.94 vs. BIOD: -44.26 )
BIOD' s 10-Year ROA (%) Range
Min: -566.19   Max: -28.58
Current: -44.26

-566.19
-28.58
ROC (Joel Greenblatt) (%) -2565.40
BIOD's ROC (Joel Greenblatt) (%) is ranked higher than
62% of the 1234 Companies
in the Global Biotechnology industry.

( Industry Median: -394.00 vs. BIOD: -2565.40 )
BIOD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2547.75   Max: -884.48
Current: -2565.4

-2547.75
-884.48
EBITDA Growth (3Y)(%) -10.90
BIOD's EBITDA Growth (3Y)(%) is ranked higher than
72% of the 699 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. BIOD: -10.90 )
BIOD' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 51.6
Current: -10.9

0
51.6
EPS Growth (3Y)(%) -21.40
BIOD's EPS Growth (3Y)(%) is ranked higher than
66% of the 721 Companies
in the Global Biotechnology industry.

( Industry Median: -6.70 vs. BIOD: -21.40 )
BIOD' s 10-Year EPS Growth (3Y)(%) Range
Min: -44   Max: 113.9
Current: -21.4

-44
113.9
» BIOD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

BIOD Guru Trades in Q4 2013

Chuck Royce 40,000 sh (New)
Jim Simons 145,500 sh (New)
» More
Q1 2014

BIOD Guru Trades in Q1 2014

Jim Simons 184,895 sh (+27.08%)
Chuck Royce 20,100 sh (-49.75%)
» More
Q2 2014

BIOD Guru Trades in Q2 2014

Jim Simons 225,653 sh (+22.04%)
Chuck Royce 20,100 sh (unchged)
» More
Q3 2014

BIOD Guru Trades in Q3 2014

Chuck Royce 20,100 sh (unchged)
Jim Simons 63,300 sh (-71.95%)
» More
» Details

Insider Trades

Latest Guru Trades with BIOD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.60
BIOD's P/B is ranked higher than
95% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 6.38 vs. BIOD: 1.60 )
BIOD' s 10-Year P/B Range
Min: 0   Max: 3.3
Current: 1.6

0
3.3
EV-to-EBIT -0.64
BIOD's EV-to-EBIT is ranked higher than
62% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BIOD: -0.64 )
BIOD' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -0.64

Current Ratio 15.41
BIOD's Current Ratio is ranked higher than
92% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. BIOD: 15.41 )
BIOD' s 10-Year Current Ratio Range
Min: 0.82   Max: 16.42
Current: 15.41

0.82
16.42
Quick Ratio 15.41
BIOD's Quick Ratio is ranked higher than
93% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. BIOD: 15.41 )
BIOD' s 10-Year Quick Ratio Range
Min: 0.82   Max: 16.42
Current: 15.41

0.82
16.42

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.60
BIOD's Price/Net Cash is ranked higher than
99% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 55.00 vs. BIOD: 1.60 )
BIOD' s 10-Year Price/Net Cash Range
Min: 0.61   Max: 6.86
Current: 1.6

0.61
6.86
Price/Net Current Asset Value 1.60
BIOD's Price/Net Current Asset Value is ranked higher than
98% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 31.07 vs. BIOD: 1.60 )
BIOD' s 10-Year Price/Net Current Asset Value Range
Min: 0.61   Max: 6.84
Current: 1.6

0.61
6.84
Price/Tangible Book 1.60
BIOD's Price/Tangible Book is ranked higher than
96% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 9.50 vs. BIOD: 1.60 )
BIOD' s 10-Year Price/Tangible Book Range
Min: 0.56   Max: 5.82
Current: 1.6

0.56
5.82
Earnings Yield (Greenblatt) -156.30
BIOD's Earnings Yield (Greenblatt) is ranked lower than
53% of the 1236 Companies
in the Global Biotechnology industry.

( Industry Median: -5.70 vs. BIOD: -156.30 )
BIOD' s 10-Year Earnings Yield (Greenblatt) Range
Min: -413.5   Max: 5045.8
Current: -156.3

-413.5
5045.8

Analyst Estimate

Sep15 Sep16 Sep17
EPS($) -0.59 -1.26 -1.84
EPS without NRI($) -0.59 -1.26 -1.84

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:BDQN.Germany,
Biodel, Inc., was incorporated in the State of Delaware on December 3, 2003 and commenced operations in January 2004. The Company is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes that might be safer, more effective and more convenient for patients. The Company develops its product candidates by applying proprietary formulation technologies to existing drugs in order to improve their therapeutic profiles. Its most advanced program involves developing proprietary formulations of injectable recombinant human insulin, or RHI, designed to be more rapid-acting than the 'rapid-acting' mealtime insulin analogs currently used to treat patients with Type 1 and Type 2 diabetes. In addition to its ultra-rapid-acting insulin formulation program, the Company is developing a liquid glucagon formulation for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia, or very low concentrations of blood glucose. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization. The FDA and other federal, state, local and foreign regulatory agencies impose substantial requirements upon the clinical development, approval, labeling, manufacture, marketing and distribution of drug products.
» More Articles for BIOD

Headlines

Articles On GuruFocus.com
cooldecency99 note on BIOD May 01 2010 
Biodel Reports Third Quarter Fiscal Year 2009 Financial Results Aug 07 2009 
Biodel to Report Third Quarter Fiscal Year 2009 Results on August 7, 2009 Aug 03 2009 
Biodel Reports First Quarter Fiscal Year 2009 Financial Results and Clinical Update Feb 05 2009 
Biodel to Report First Quarter Fiscal Year 2009 Results and Top Line Results of Bioequivalence Study Jan 30 2009 
Biodel Inc. Reports Fourth Quarter and Fiscal Year 2008 Financial Results Dec 10 2008 


More From Other Websites
Nasdaq stocks posting largest volume increases Jan 26 2015
Shire's Elvanse Gets Positive Response for ADHD in Adults - Analyst Blog Jan 26 2015
Will Novartis' (NVS) Earnings Disappoint Expectations in Q4? - Analyst Blog Jan 23 2015
UCB's New Epilepsy Drug Under Review in the U.S., EU - Analyst Blog Jan 22 2015
Valeant's Bausch + Lomb Imaging System Cleared by FDA - Analyst Blog Jan 21 2015
CytRx Relieved as FDA Lifts Partial Hold on Oncology Drug - Analyst Blog Jan 21 2015
Immunomedics Reports Data on Oncology Candidate - Analyst Blog Jan 21 2015
ARIAD's Iclusig Endorsed by EC for All Approved Indications - Analyst Blog Jan 21 2015
Novo Nordisk's Xultophy to Launch First in Switzerland - Analyst Blog Jan 20 2015
UCB-Neuropore Collaborate for Parkinson's Disease Therapy - Analyst Blog Jan 19 2015
Sarepta Starts Dosing in Duchenne Muscular Dystrophy Study - Analyst Blog Jan 15 2015
Regado Biosciences to Merge with Tobira Therapeutics - Analyst Blog Jan 15 2015
US pre-open: Futures rise on wake of dovish Fed comment Jan 08 2015
Wednesday's After-Hours Movers Jan 07 2015
BIODEL INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 07 2015
Biodel's Concentrated Insulin BIOD-531 Demonstrates Superior Post-Meal Glucose Control Compared to... Jan 07 2015
BIODEL INC Financials Dec 30 2014
10-K for Biodel, Inc. Dec 21 2014
BIODEL INC Files SEC form 10-K, Annual Report Dec 19 2014
BIODEL INC Files SEC form 8-K, Results of Operations and Financial Condition Dec 17 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK